Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. It offers software that is compatible with off-the-shelf, mobile client devices, which enables clinicians to communicate with remotely located documentation specialists (RDSs). The company's services include Augmedix Live, a real time service, in which RDSs provide medical documentation and live clinical support services; and Augmedix Notes, a non-real time product where RDSs offer medical documentation based upon recorded visits. Its clients include health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.
IPO Year:
Exchange: NASDAQ
Website: augmedix.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/22/2024 | Buy → Hold | Lake Street | |
| 7/22/2024 | $3.00 → $2.35 | Buy → Neutral | B. Riley Securities |
| 5/14/2024 | $5.00 | Buy → Hold | Maxim Group |
| 5/14/2024 | $5.00 → $1.50 | Outperform → In-line | Evercore ISI |
| 4/3/2024 | $5.50 | Buy | B. Riley Securities |
| 12/15/2023 | $6.00 | In-line | Evercore ISI |
| 3/7/2022 | $6.00 | Buy | Lake Street |
| 1/21/2022 | $6.00 | Buy | Maxim Group |
| 11/1/2021 | $6.00 | Buy | Benchmark |
| 11/1/2021 | Outperform | William Blair |
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
15-12G - Augmedix, Inc. (0001769804) (Filer)
EFFECT - Augmedix, Inc. (0001769804) (Filer)
EFFECT - Augmedix, Inc. (0001769804) (Filer)
EFFECT - Augmedix, Inc. (0001769804) (Filer)
25-NSE - Augmedix, Inc. (0001769804) (Subject)
S-8 POS - Augmedix, Inc. (0001769804) (Filer)
S-8 POS - Augmedix, Inc. (0001769804) (Filer)
S-8 POS - Augmedix, Inc. (0001769804) (Filer)
S-8 POS - Augmedix, Inc. (0001769804) (Filer)
POS AM - Augmedix, Inc. (0001769804) (Filer)
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
4 - Augmedix, Inc. (0001769804) (Issuer)
Lake Street downgraded Augmedix from Buy to Hold
B. Riley Securities downgraded Augmedix from Buy to Neutral and set a new price target of $2.35 from $3.00 previously
Maxim Group downgraded Augmedix from Buy to Hold and set a new price target of $5.00
Evercore ISI downgraded Augmedix from Outperform to In-line and set a new price target of $1.50 from $5.00 previously
B. Riley Securities resumed coverage of Augmedix with a rating of Buy and set a new price target of $5.50
Evercore ISI initiated coverage of Augmedix with a rating of In-line and set a new price target of $6.00
Lake Street initiated coverage of Augmedix with a rating of Buy and set a new price target of $6.00
Maxim Group initiated coverage of Augmedix with a rating of Buy and set a new price target of $6.00
Benchmark initiated coverage of Augmedix with a rating of Buy and set a new price target of $6.00
William Blair initiated coverage of Augmedix with a rating of Outperform
SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic
SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. "We believe we are approaching the proposed combination with Commure, Inc. from a position of strength, with consistent double-digit revenue growth and improving gross margins," commented Manny Krakaris, Augmedix CEO. "Together, we believe we will be well-positioned to continue to streamline the medical documentation ecosystem with a growing base of health system customers, solid partners, and proven solutions. As part of Commure, we expect to scale our ambient documentation solu
SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and
SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced that it has entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems, in an all-cash transaction that values Augmedix at approximately $139 million in equity value. Under the terms of the agreement, Augmedix stockholders will receive $2.35 per share in cash upon completion of the proposed transaction, and Augmedix will become a wholly-owned subsidiary of Commure. The purchase price represents a premium of approximately 169% over the volume weighted average price
SAN FRANCISCO, June 20, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today that Emergency Services Inc., a physician-owned emergency medicine services group in Columbus, Ohio, is introducing Augmedix Go ED to physicians in the emergency department (ED) at the second-largest healthcare system in central Ohio. Augmedix Go ED is the industry's first fully automated, generative AI (GenAI) powered medical documentation product for EDs nationwide. "Given the unique needs of the ED, it has been difficult to identify a documentation solution that effectively alleviates the administrative burden on our physicians – unt
SAN FRANCISCO, June 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reiterated its expectations in advance of management's participation at the William Blair Annual Growth Stock Conference. Management continues to expect second quarter 2024 revenue to increase slightly sequentially from the first quarter of 2024, and second quarter 2024 GAAP gross margins to increase from the first quarter of 2024 by 50 to 100 basis points. For the full year of 2024, management continues to expect revenue of approximately $52 to $55 million. Management will present at the William Blair Annual Growth Stock Conference (Chicago) on
SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient artificial intelligence (AI) medical documentation and data solutions, today announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. "Welcoming Dr. Stinard to join Augmedix in this new role is an exciting step forward in implementing advanced AI technolog
SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024. "Augmedix delivered in-line first quarter performance, with 40% revenue growth, 143% net revenue retention and 47.1% gross margins," commented Manny Krakaris, Augmedix CEO. "We are confident about our positioning within the medical documentation market, and expect to report continued growth throughout the rest of the year. It is now clear, however, that health systems are proceeding methodically while they develop a better understanding of the capabilities of AI products." "We a
SAN FRANCISCO, May 03, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced that its management team will participate in the following four investor conferences in May and June 2024. RBC Capital Markets Global Healthcare Conference (New York): Management will participate in a fireside chat on May 15 at 10:30 a.m. ET, and be available for 1x1 investor meetings. The webcast link for the fireside chat can be found at https://ir.augmedix.com/.Benchmark Healthcare House Call Conference (Virtual): Management will be available for 1x1 investor meetings on May 21.B. Riley Annual Institutional Investor Conference (B
SAN FRANCISCO, April 30, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it will release first quarter 2024 results after the market closes on Monday, May 13, 2024. Following the release, management will host a conference call that same day at 1:30 p.m. PT / 4:30 p.m. ET. Live conference call: 877-407-3982 (Toll-Free) and 201-493-6780 (International)Live webcast: https://viavid.webcasts.com/starthere.jsp?ei=1666696&tp_key=f217dd82fa An archived replay will be available following the call on Augmedix's IR website at https://ir.augmedix.com/. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to conn
SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced that it has entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems, in an all-cash transaction that values Augmedix at approximately $139 million in equity value. Under the terms of the agreement, Augmedix stockholders will receive $2.35 per share in cash upon completion of the proposed transaction, and Augmedix will become a wholly-owned subsidiary of Commure. The purchase price represents a premium of approximately 169% over the volume weighted average price
SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient artificial intelligence (AI) medical documentation and data solutions, today announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. "Welcoming Dr. Stinard to join Augmedix in this new role is an exciting step forward in implementing advanced AI technolog
SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced its go-to-market partnership with SADA, an Insight company, a leading cloud business and technology consultancy. The collaboration is focused on leveraging the companies' combined technology expertise and expanding their reach to provide greater product and service value to health systems seeking high-quality ambient documentation and structured data products. "We are thrilled to join forces with SADA, to partner with an organization that has a nationwide reach to health systems, and also to leverage their prowess in frontier cloud infr
SAN FRANCISCO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that Tomer Levy joined the company in January 2024 in the newly-created Senior Vice President of Engineering role. Levy brings over 20 years of experience in healthcare information technology. Throughout his career, he has delivered innovative solutions in healthcare IT to large enterprises worldwide. "We are thrilled to have Tomer join Augmedix as we continue to push the boundaries of AI-powered medical documentation technology to alleviate administrative burden," said Manny Krakaris,
SAN FRANCISCO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced the appointment of its inaugural AI Advisory Council members. The council was established to guide Augmedix's continued development and usage of artificial intelligence (AI) throughout its business responsibly and ethically. The council is composed of a diverse group of experts, including leading researchers in AI, to advise on the development of new technologies for natural language processing (NLP) and intelligent user interfaces (IUI); bioinformaticians to speak to the appropriate and best
SC 13D/A - Augmedix, Inc. (0001769804) (Subject)
SC 13G - Augmedix, Inc. (0001769804) (Subject)
SC 13D/A - Augmedix, Inc. (0001769804) (Subject)
SC 13G/A - Augmedix, Inc. (0001769804) (Subject)
SC 13D/A - Augmedix, Inc. (0001769804) (Subject)
SC 13G - Augmedix, Inc. (0001769804) (Subject)
SC 13D/A - Augmedix, Inc. (0001769804) (Subject)
SC 13D/A - Augmedix, Inc. (0001769804) (Subject)
SC 13D/A - Augmedix, Inc. (0001769804) (Subject)
SC 13D/A - Augmedix, Inc. (0001769804) (Subject)
SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic
SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and
SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024. "Augmedix delivered in-line first quarter performance, with 40% revenue growth, 143% net revenue retention and 47.1% gross margins," commented Manny Krakaris, Augmedix CEO. "We are confident about our positioning within the medical documentation market, and expect to report continued growth throughout the rest of the year. It is now clear, however, that health systems are proceeding methodically while they develop a better understanding of the capabilities of AI products." "We a
SAN FRANCISCO, April 30, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it will release first quarter 2024 results after the market closes on Monday, May 13, 2024. Following the release, management will host a conference call that same day at 1:30 p.m. PT / 4:30 p.m. ET. Live conference call: 877-407-3982 (Toll-Free) and 201-493-6780 (International)Live webcast: https://viavid.webcasts.com/starthere.jsp?ei=1666696&tp_key=f217dd82fa An archived replay will be available following the call on Augmedix's IR website at https://ir.augmedix.com/. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to conn
SAN FRANCISCO, March 18, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three and 12 months ended December 31, 2023. "The fourth quarter was a solid end to a strong year for Augmedix both operationally and financially," stated Augmedix CEO Manny Krakaris. "We delivered a 45% increase in revenue to $12.7 million, ahead of our most recent guidance, driven by a 44% increase in clinicians in service and net revenue retention of 152%. Additionally, we made steady progress toward our profitability goals by increasing gross profit by 54% to $6.2 million, a margin expansion of 300 basis poi
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today it will release fourth quarter and full year 2023 results after the market closes on Monday, March 18, 2024. Following the release, management will host a conference call and audio webcast to review results and provide a brief business and outlook update that same day at 1:30 p.m. PT / 4:30 p.m. ET. Live conference call: 877-407-3982 (Toll-Free) and 201-493-6780 (International)Live webcast: https://viavid.webcasts.com/starthere.jsp?ei=1656407&tp_key=3507378dc0 An archived replay will be
SAN FRANCISCO, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (NASDAQ:AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced preliminary revenue results and operational metrics for the fourth quarter of 2023. "Augmedix's expected fourth quarter revenue of approximately $12.5 million puts us on pace to deliver a solid finish to a strong year," stated Augmedix CEO Manny Krakaris. "We enter 2024 with approximately $51 million in expected Annual Recurring Revenue, driven by strong adoption of Augmedix Live and Augmedix Notes by our health system customers. With Augmedix Go now generally available in the ambulat
SAN FRANCISCO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, reported today financial results for the three and nine months ended September 30, 2023. "The third quarter marked another period of strong progress for Augmedix as we continue to be a leader in the large and rapidly growing ambient medical documentation market," commented Manny Krakaris, Chief Executive Officer at Augmedix. "Growing adoption of Augmedix Live and Augmedix Notes drove 50% revenue growth and net revenue retention of 157%, while expanding gross margins by 390 basis points to 49.5%. With stron
SAN FRANCISCO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today it will report financial results for the third quarter ended September 30, 2023, on Monday, November 6, 2023, after the market closes. Management will host a conference call that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the conference call will be available on the "Events" section of the Company's website at: https://ir.augmedix.com/news-events. Alternatively, interested parties can dial 877-407-3982 (toll-free) or 201-493-6780 (international) to listen. The we
SAN FRANCISCO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners, today reported financial results for the three and six months ended June 30, 2023. "This was another strong quarter for Augmedix, as we continue to solidify our position within the burgeoning ambient medical documentation market," commented Manny Krakaris, Chief Executive Officer at Augmedix. "We set records for revenue, growing 47% year-over-year, and dollar-based net revenue retention at 148%, demonstrating that healt